Literature DB >> 28392582

Does CIN2 Have the Same Aggressive Potential As CIN3? A Secondary Analysis of High-Grade Cytology Recurrence in Women Treated with Cold-Coagulation Cervical Treatment.

D Papoutsis1, M Underwood1, W Parry-Smith1, J Panikkar1.   

Abstract

Introduction To determine whether women with CIN2 versus CIN3 on pretreatment cervical punch biopsy have less high-grade cytology recurrence following cold-coagulation cervical treatment. Materials and Methods This was a retrospective study of women having had cold coagulation between 2001-2011 in our colposcopy unit. Women with previous cervical treatment were excluded. Results We identified 402 women with 260 (64.7 %) cases of CIN2 and 142 (35.3 %) cases of CIN3 on pretreatment cervical punch biopsy. In the total sample, the mean age of women was 27.5 years (SD = 4.9), 75.1 % were nulliparous and 36.6 % were smokers. Referral cytology and pretreatment colposcopic appearance were high-grade in 62.7 % and 57.1 %. The mean follow-up period was 2.8 years (SD = 2.1). Women with CIN2 on pretreatment cervical biopsy when compared to those with CIN3 had less frequently high-grade referral cytology and high-grade pretreatment colposcopic appearances, and had less pretreatment cervical biopsies taken. During the follow-up period, women with CIN2 on pretreatment cervical biopsy had less high-grade cytology recurrence when compared to those women with CIN3 (1.9 vs. 5.6 %, p = 0.046). Multiple stepwise Cox regression analysis showed that women with CIN3 on pretreatment cervical biopsy had 3.21 times greater hazard for high-grade cytology recurrence (HR = 3.21, 95 % CI: 1.05-9.89; p = 0.041) in comparison with CIN2 cases. Conclusion We found that women with CIN2 on pretreatment cervical punch biopsy had less high-grade cytology recurrence following cold-coagulation treatment in comparison to those with CIN3. This finding lends support to the theory that CIN2 even though a high-grade abnormality might not have the same aggressive potential as CIN3.

Entities:  

Keywords:  CIN; cold coagulation; cytology recurrence

Year:  2017        PMID: 28392582      PMCID: PMC5383435          DOI: 10.1055/s-0042-119993

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  26 in total

1.  Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women.

Authors:  Anna-Barbara Moscicki; Yifei Ma; Charles Wibbelsman; Teresa M Darragh; Adaleen Powers; Sepideh Farhat; Stephen Shiboski
Journal:  Obstet Gynecol       Date:  2010-12       Impact factor: 7.661

2.  Success rate of cold coagulation for the treatment of cervical intraepithelial neoplasia: a retrospective analysis of a series of cases.

Authors:  William Parry-Smith; Martyn Underwood; Sabrina De Bellis-Ayres; Laura Bangs; Charles W E Redman; Jane Panikkar
Journal:  J Low Genit Tract Dis       Date:  2015-01       Impact factor: 1.925

3.  Outcome of expectant management of cervical intraepithelial neoplasia grade 2 in women followed for 12 months.

Authors:  Michelle G Discacciati; Carlos André S de Souza; Maria Gabriela d'Otavianno; Liliana A L Ângelo-Andrade; Maria Cristina A Westin; Silvia H Rabelo-Santos; Luiz C Zeferino
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2010-12-28       Impact factor: 2.435

Review 4.  Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers.

Authors:  J P A Baak; A-J Kruse; S J Robboy; E A M Janssen; B van Diermen; I Skaland
Journal:  J Clin Pathol       Date:  2006-05-05       Impact factor: 3.411

5.  Reliability and relationship of colposcopical, cytological and histopathological findings in the diagnostic process.

Authors:  Vera Milenković; Radmila Sparić; Jelena Dotlić; Lidija Tulić; Ljiljana Mirković; Svetlana Milenković; Jasmina Atanacković
Journal:  Vojnosanit Pregl       Date:  2012-10       Impact factor: 0.168

6.  The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study.

Authors:  Paolo Dalla Palma; Paolo Giorgi Rossi; Guido Collina; Anna Maria Buccoliero; Bruno Ghiringhello; Eliana Gilioli; Gian Libero Onnis; Daniela Aldovini; Giuseppe Galanti; Gianpiero Casadei; Mirella Aldi; Vito V Gomes; Pamela Giubilato; Guglielmo Ronco
Journal:  Am J Clin Pathol       Date:  2009-07       Impact factor: 2.493

7.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.

Authors:  Margaret R E McCredie; Katrina J Sharples; Charlotte Paul; Judith Baranyai; Gabriele Medley; Ronald W Jones; David C G Skegg
Journal:  Lancet Oncol       Date:  2008-04-11       Impact factor: 41.316

8.  Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: a quantitative survey.

Authors:  Ovadia Abulafia; John C Pezzullo; David M Sherer
Journal:  Gynecol Oncol       Date:  2003-07       Impact factor: 5.482

Review 9.  Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  BMC Infect Dis       Date:  2009-07-29       Impact factor: 3.090

Review 10.  Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia.

Authors:  Maria Kyrgiou; Anita Mitra; Marc Arbyn; Maria Paraskevaidi; Antonios Athanasiou; Pierre P L Martin-Hirsch; Phillip Bennett; Evangelos Paraskevaidis
Journal:  Cochrane Database Syst Rev       Date:  2015-09-29
View more
  1 in total

1.  The role of EP-2 receptor expression in cervical intraepithelial neoplasia.

Authors:  Elisa Schmoeckel; Patricia Fraungruber; Christina Kuhn; Udo Jeschke; Sven Mahner; Theresa Maria Kolben; Thomas Kolben; Theresa Vilsmaier; Anna Hester; Helene Hildegard Heidegger
Journal:  Histochem Cell Biol       Date:  2020-08-26       Impact factor: 4.304

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.